Trial Profile
Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Carvedilol (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms PREVENT-HF
- 09 Jan 2024 Results evaluating the activity and safety of low-dose carvedilol for heart failure risk reduction in childhood cancer survivors at highest risk for heart failure, published in the Lancet Oncology
- 17 Oct 2023 Planned End Date changed from 30 Sep 2023 to 30 Sep 2024.
- 06 Jun 2023 Primary endpoint (Left ventricular (LV) thickness-dimension ratio (LVT-D) derived from echocardiogram, reported in terms of LV posterior wall dimension in systole and LV dimension based on the internal diameter in diastole) has been met, as per results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.